

Cite this: *RSC Adv.*, 2017, 7, 51391

## Structural features of FAP174, a MYCBP-1 orthologue from *Chlamydomonas reinhardtii*, revealed by computational and experimental analyses†

M. Yogesha,<sup>a</sup> Venkatramanan G. Rao,<sup>b</sup> Elvis A. F. Martis,<sup>c</sup> Evans C. Coutinho,<sup>c</sup> Holger Gohlke,<sup>d</sup> Santhosh Chidangil,<sup>a</sup> Prabhakar M. Dongre<sup>e</sup> and Jacinta S. D'Souza<sup>id</sup>\*<sup>ab</sup>

The dimers of regulatory sub-units of protein kinase A (RI $\alpha$ , RII $\alpha$ , RI $\beta$ , and RII $\beta$  isoforms) and DPY-30 interact with their respective A-Kinase Anchoring Proteins (AKAPs) via their Dimerization and Docking domains (D/D). The mammalian MYCBP-1 protein, which stimulates the E-box-dependent transcriptional activity of the c-Myc protein, also interacts with AKAPs present in various sub-cellular locales. We have earlier shown that the Flagellar Associated Protein 174 (FAP174) from *Chlamydomonas reinhardtii* is an orthologue of human MYCBP-1 and binds to AKAP240. Here, we set out to identify the D/D domain of FAP174 and the amino acid residues involved in oligomerization. By means of electrophoresis of recombinant proteins with an increasing concentration of a reducing agent (DTT), MALDI-TOF, FT-IR, and micro-Raman spectroscopy, we show that the D/D domain resides in and around the C46 residue. Using *in silico* methods, we infer that the neighboring amino acids of C46, viz. A39, L40, Y42, and L47, might also be involved in dimerization. The secondary structure of FAP174 was investigated using computer-assisted prediction, CD, micro-Raman spectroscopy, and FT-IR. Accordingly, FAP174 is made of four  $\alpha$ -helices. Helix B contains two VLV stretches at positions 21–23 and 25–27. Mutating these VLV stretches to alanines followed by native gel electrophoresis of the respective recombinant proteins indicated their role in oligomerization. The results imply that FAP174, unlike most of the other AKAP-interacting proteins, harbors two different domains, one for dimerization and the other for oligomerization.

Received 16th July 2017  
Accepted 27th October 2017

DOI: 10.1039/c7ra07836f

rsc.li/rsc-advances

## 1. Introduction

cAMP is a second messenger that mediates most of its effects through cAMP-dependent protein kinase (PKA) and controls a broad spectrum of cellular events<sup>1</sup> through crucial intracellular organization involving the A-Kinase Anchoring Proteins (AKAPs).<sup>2</sup> AKAPs can bind to multiple signaling proteins forming modules or units that provide the 'anchor' or 'scaffold' for

the integration of different signaling pathways. To understand this complex signaling assemblies, it is crucial to identify and isolate these units, the interacting partners, and their interacting domains.

A less known protein in one such AKAP complex is MYCBP-1 or Associate of Myc-1 (AMY-1). Originally identified as a c-Myc-binding protein, it stimulates the E-box-dependent transcriptional activity of the c-Myc protein, which plays key roles in several cellular processes. After expression, MYCBP-1 translocates from the cytoplasm to the nucleus,<sup>3</sup> acting there as a co-transcription factor.<sup>4</sup> For regulation, MYCBP-1 forms a ternary complex with S-AKAP84/AKAP149 and the regulatory subunit (RII) of PKA<sup>5–7</sup> in the mitochondria. In addition, MYCBP-1 independently binds to the RII-Binding Domain (RII-BD) of AKAP149 and AKAP95<sup>6,7</sup> and interacts with various other AKAPs.<sup>5–8</sup> All known AKAPs harbor a RII-BD that comprises an amphipathic helix.<sup>9</sup> However, the mechanistic details of these interactions have remained elusive. Meanwhile, there has been an immense progress on the structure elucidation of PKA and AKAPs; and, with no understanding of the biochemical features (including dimerization and/or oligomerization) and the

<sup>a</sup>Department of Atomic & Molecular Physics, Manipal University, Manipal 576104, India

<sup>b</sup>UM-DAE Centre for Excellence in Basic Sciences, Kalina Campus, Santacruz (E), Mumbai-400098, India. E-mail: jacinta@cbs.ac.in; Fax: +91-22-26524983; Tel: +91-22-26524978

<sup>c</sup>Molecular Simulations Group, Department of Pharmaceutical Chemistry, Bombay College of Pharmacy, Kalina, Santacruz (E), Mumbai 400098, India

<sup>d</sup>Mathematisch-Naturwissenschaftliche Fakultät, Institut für Pharmazeutische und Medizinische Chemie, Heinrich-Heine-Universität Düsseldorf, 40225 Düsseldorf, Germany

<sup>e</sup>Department of Biophysics, University of Mumbai, Kalina Campus, Santacruz (E), Mumbai-400098, India

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c7ra07836f

structure of MYCBP-1 and its orthologues such as FAP174, the biological function of this signaling unit has remained unanswered.

Interestingly, MYCBP-1 was also found in the human ciliary proteome (NCBI accession no. ACR55627).<sup>10</sup> Subsequently, Flagellar Associated Protein 174 (FAP174), a component of the *C. reinhardtii* ciliary proteome, was identified as a MYCBP-1 homologue.<sup>11</sup> Our experiments revealed that FAP174 binds to AKAP240; both these proteins being localized to the central pair of the axoneme. Additionally, FAP174 was found to be localized to the nucleus and basal body.<sup>12</sup> We then set out to search for a D/D domain on FAP174; this domain allows AKAP-binding proteins to interact with the amphipathic helix of all AKAPs as dimers.<sup>13</sup> We hypothesized that the only cysteine at position 46 of the FAP174 sequence could contribute to forming a dimer *via* a disulfide bridge. Furthermore, a multiple sequence alignment of FAP174 with other AKAP-interacting proteins such as RII and DPY-30 revealed two conserved VLV stretches at positions 21–23 and 25–27.<sup>12</sup>

Building upon these previous results, here, we investigate the role of C46 and the two conserved VLV stretches on the secondary structure and oligomerization properties of FAP174. We did so by applying conventional gel electrophoresis after subjecting wild-type (WT) FAP174 and FAP174 variant proteins (FAP174VLV21–23AAA, FAP174VLV25–27AAA and FAP174C46A) with an increasing concentration of a reducing agent such as DTT, biophysical techniques such as MALDI-TOF, CD, FT-IR, and micro-Raman spectroscopy, as well as *ab initio* protein structure prediction and molecular dynamics (MD) simulations. Our results imply that FAP174, unlike most of the other AKAP-interacting proteins, harbors two different domains, one for dimerization and the other for oligomerization.

## 2. Materials and methods

The biochemical reagents and media components were obtained from Amresco (USA), SRL (India), Merck Millipore (India) and Qiagen (Germany).

### 2.1 Mass determination of proteins

The FAP174 WT and mutant genes were cloned in pET28a vector and over-expressed in *E. coli* BL21(DE3) cells. The 6XHis-tagged proteins were individually purified using a NiNTA-agarose column.<sup>12</sup> The purity of the proteins was determined by electrophoresis of the purified fractions on a 15% SDS-PAGE gel followed by the standard silver staining method. The masses of the samples were determined using the Mass Spectrometry facility at the Tata Institute of Fundamental Research (Mumbai, India). Briefly, ~3000 ng  $\mu\text{L}^{-1}$  of the purified proteins were mixed individually with the matrix sinapinic acid and spotted onto the MALDI-TOF plate. The samples were allowed to dry at room temperature. The plate was then loaded on the machine and spectra developed in the linear mode.

### 2.2 Effect of DTT on dimerization of FAP174 WT and variant proteins

For this assay, 10  $\mu\text{g}$  of each protein sample was treated with an increasing concentration (0–250 mM) of DTT followed by incubation at room temperature for 5 minutes. The samples were then treated with Laemmli buffer (without any reducing agent) followed by electrophoresis on a 15% SDS-PAGE gel. The polypeptides were evident after Coomassie Blue R-250 staining.

### 2.3 Biophysical characterization of FAP174 and its variants

The secondary structure of FAP174 WT and three variants were determined using a JASCO CD Polarimeter J-810. The spectra were measured using a cuvette with 1 mm path length. The CD spectra of these proteins were measured from 190–260 nm with a band width of 1 nm and a speed of 50 nm  $\text{s}^{-1}$ . The samples, at a concentration of 0.1 mg  $\text{mL}^{-1}$ , were individually suspended in 10 mM phosphate buffer, pH 7.0 and the chamber was continuously flushed with  $\text{N}_2$  gas. The resultant spectral values are expressed in units of delta epsilon ( $\Delta\epsilon$ ). The secondary structure of FAP174 WT and variants were analyzed by deconvolution of the CD spectrum using the online BeStSel analysis program<sup>14</sup> applied at the wavelength range of 190–250 nm.

FT-IR spectra of the lyophilized proteins were recorded at room temperature by mixing with KBr and pressing to form discs. The FTIR measurement was carried out using a JASCO 6300 FT-IR spectrometer equipped with a DLATGS detector and a standard source. Two hundred scans with 2  $\text{cm}^{-1}$  spectral resolution were obtained. Approximately, 2 mg of pure lyophilized protein powder was used to obtain the Raman spectra using a Horiba Jobin-Yvon Spectrometer with an inverted microscope (Nikon Eclipse Ti-U, Japan). A diode laser (Star-bright Diode Laser, Torsana Laser Tech, Denmark) with wavelength of 785 nm and 47 mW power was used to illuminate the protein samples sandwiched between the quartz coverslip and the borosilicate glass slide. Symphony CCD detector cooled under liquid nitrogen was utilized to collect the Raman scattered radiation from the sample.

### 2.4 Secondary structure prediction

The predictions of the secondary structure and the helical content of FAP174 WT and three variants were studied using five well-known methods<sup>15–22</sup> available as online web servers. Table 1 enlists the web servers and their methodologies used to predict the secondary structures of proteins. Since predictions are highly sensitive to the method used, results from all five servers were used to draw a consensus picture of the secondary structure.

### 2.5 Tertiary structure prediction

The tertiary structure of FAP174 WT and its three variants were predicted by the *ab initio* method implemented in the QUARK program available as an online server<sup>22</sup> and by the threading method implemented in the I-TASSER webserver.<sup>19</sup> QUARK requires no templates for structure prediction, as it assembles the protein structure from models of small fragments (1–20



**Table 1** List of webserver used for the prediction of secondary structure of the proteins

Webserver	Method
LOMETS implemented in I-TASSER21	Local meta-threading approach
PSIPRED17, 18	Two-stage neural network based on protein specific scoring matrices generated by PSI-BLAST
QUARK22	Neural networks
GOR V20	Combination of information theory, Bayesian statistics and evolutionary information
JPRED15, 16	Jnet algorithm

residues long) by replica-exchange Monte Carlo simulation guided by an atomic-level knowledge-based force field. I-TASSER retrieves templates from the Protein Data Bank and threads the query sequence over the folds on the template proteins. For the unaligned regions in the query sequence, I-TASSER employs the QUARK methodology to predict the folds.

Our previous studies showed that FAP174 WT binds to AKAPs<sup>12</sup> akin to DPY-30 (PDB id 3G36<sup>23</sup>) and RII $\alpha$  D/D (PDB id 2IZX<sup>24</sup>) proteins. To determine the relationship between the structures of FAP174 WT, DPY-30 and RII $\alpha$  D/D, all predicted 3D-models of FAP174 WT were superimposed onto the crystal structures of DPY-30 and RII $\alpha$  D/D proteins. The superimposition (protein structure alignment) was performed with Maestro – the graphical user interface in Schrödinger Suite 2015-1. The QUARK model 3, which showed the lowest all atom RMSD with respect to DPY-30 and RII $\alpha$  D/D (see results and discussion) was selected, and from it the 3D models for the variants (FAP174VLV21-23AAA, FAP174VLV25-27AAA and FAP174C46A) were generated by replacing the sidechain atoms of valine/leucine/cysteine by CH<sub>3</sub> of alanine.

## 2.6 Refinement of the 3D models by molecular dynamics simulations

The AMBER14 suite<sup>25</sup> was used to perform molecular dynamics (MD) simulations. The Amber force field 14 (ff14SB)<sup>26,27</sup> was employed to represent the proteins. The TIP3P water model<sup>28</sup> was used to solvate the proteins in a periodic truncated octahedral box. The dimensions of the solvent box were extended 12.0 Å beyond the solute atoms. The system was relaxed using three cycles of minimization of 50 000 steps each, wherein the first 10 000 steps adopted the steepest descent minimizer and the remaining 40 000 steps used the conjugate gradient minimizer, with the cut-off for non-bonded interactions set to 8.0 Å. The first cycle of minimization was performed with a restraining harmonic potential and a force constant of 25 kcal (mol<sup>-1</sup> Å<sup>-2</sup>) on the solute atoms, the force constant was lowered to 5 kcal (mol<sup>-1</sup> Å<sup>-2</sup>) in the next cycle, and the last cycle was performed without any restraining forces. The system was heated, under the NVT ensemble, from 0 K to 300 K over a period of 1 ns with a restraining harmonic potential and a force constant of 5 kcal (mol<sup>-1</sup> Å<sup>-2</sup>) on the solute atoms by Langevin dynamics and a collisional frequency of 2.0 ps<sup>-1</sup>. After heating, the system was equilibrated, under the NVT ensemble, for six cycles of 1 ns each, where the force constants of the restraining potentials on the solute atoms were gradually reduced from 5.0 to 0.0 kcal (mol<sup>-1</sup> Å<sup>-2</sup>). The next step employed the NPT ensemble for equilibration for another six

cycles (1 ns each), wherein the force constants of the restraining potentials on the solute atoms was gradually lowered from 5.0 to 0.0 kcal (mol<sup>-1</sup> Å<sup>-2</sup>). In both equilibration phases (NVT and NPT), the cut-off for the non-bonded interactions was set to 9.0 Å.

The production MD runs, in triplicate, for all the systems were performed at 300 K and 1 bar for a timescale of 1  $\mu$ s (total of 3  $\mu$ s for each system), the integration time step being 2 fs. Long-range electrostatic interactions were evaluated with the particle mesh Ewald method,<sup>29</sup> and the cut-off for non-bonded interactions during the production phase was fixed at 10.0 Å. All bonds involving hydrogen atoms were restrained using the SHAKE algorithm.<sup>30</sup> The coordinates were sampled every 50 ps and then analyzed with respect to mass-weighted backbone-RMSD and all-atom RMSF (root mean square fluctuation) along with the radius of gyration, using the CPPTRAJv15.00<sup>31</sup> tool available in AmberTools15.

## 2.7 Validation of 3D models

The models predicted by QUARK were validated using the program ANOLEA.<sup>32</sup> It performs an assessment of protein structures by several methods. The quality of the models before and after MD refinement were assessed using the QMEAN6 score.<sup>33</sup> This is a consensus score built from a linear combination of six terms (C $\beta$  interaction energy, all-atom pairwise energy, solvation energy, torsion angle energy, secondary structure agreement and solvent accessibility agreement). The Z-scores were calculated from high-resolution experimental structures of similar size, which have been resolved by X-ray crystallography. A higher QMEAN6 score, with a positive Z-score, indicates a superior quality of the model. The C $\beta$  interaction energy evaluates long-range interactions at the residue level for the  $\beta$  carbon atoms of the proteins, whereas the all-atom pairwise energy evaluates the long-range interactions for all the atoms. The local backbone geometry was evaluated by the torsion angle potential, which is computed over three consecutive amino acids. The burial of residues was analyzed by the solvation energy. The secondary structure agreement term relates the predicted secondary structure of the target sequence (calculated by PSIPRED)<sup>17</sup> with the DSSP predicted secondary structure of the model. Finally, the solvent accessibility agreement term connects the predicted relative solvent accessibility (buried/exposed) from ACCpro<sup>34</sup> with the relative solvent accessibility derived from DSSP.<sup>35</sup>



### 3. Results and discussion

#### 3.1 Identification of the oligomerization control motifs and dimerization *via* the disulfide bond

FAP174 WT harbors only one cysteine at position 46 that could be involved in dimerization through formation of a disulfide bond. When recombinant FAP174 WT protein was purified using NiNTA-agarose with >95% purity and freshly electrophoresed on a denaturing SDS-PAGE gel, two species were observed; a monomer and a dimer at ~12.5 and ~25 kDa, respectively (Fig. S1,† lane 1). The same species were observed at 12.59 kDa and 25.12 kDa when analyzed using MALDI-TOF (Fig. S2†). We assume that this results from the presence of the reducing agent 2-mercaptoethanol that does not completely reduce the protein to its monomeric state. In fact, under non-denaturing and non-reducing conditions, the protein forms higher order oligomers that are poorly resolved by electrophoresis on a 10% native gel (Fig. S3,† lane 1). To understand how certain residues in the protein affect the dimerization/oligomerization status, three FAP174 variants were generated, including a C46A mutation as well as alanine mutations of the conserved VLV stretches at position 21–23 and 25–27 (FAP174VLV21–23AAA, FAP174VLV25–27AAA and FAP174C46A). The mutant genes were synthesized, sub-cloned in a pET28a expression vector and over-expressed in *E. coli*. Individual recombinant variant proteins were then purified using NiNTA-agarose affinity chromatography (Fig. S1†). These samples were prepared in Laemmli buffer containing 50 mM of the reducing agent 2-mercaptoethanol that does not completely reduce the protein. Therefore, both monomers and dimers were evident in all the samples, except in the case of FAP174C46A. Again, these samples, after dialysis, were analyzed for their masses using MALDI-TOF. Their molecular weights were 12.36 kDa and 24.66 kDa for both the VLV variants (FAP174VLV21–23AAA and FAP174VLV25–27AAA). However, for FAP174C46A, only one species at 12.35 kDa was obtained (Fig. S2†). Therefore, under the partly reducing conditions, there exists an equilibrium between the populations of monomers and dimers of FAP174 WT, FAP174VLV21–23AAA, and FAP174VLV25–27AAA, but not FAP174C46A. Hence, these results demonstrate that C46 is the primary cause for dimerization of FAP174. Retaining C46 but removing the VLVs individually leads exclusively to the formation of dimers under non-reducing conditions (Fig. S2†), contributing further evidence to the fact that C46 is the only cause for dimerization.

In addition, the cysteine and VLV stretches were observed to have a function in promoting the protein to oligomerize as seen in the WT protein on the native gel (Fig. S3,† lane 1). Further, these oligomers exist as monomers and dimers in the presence of a partly reducing agent and denaturing conditions, where C46 sometimes retains a disulfide bridge (Fig. S1†). When the cysteine is substituted with an alanine, the VLVs alone are unable to promote oligomerization (Fig. S3†), indicating that oligomers form from dimers, rather than monomers. In turn, the presence of cysteine and the absence of either one of the VLVs forces the protein to form dimers (Fig. S3†). This is the

first evidence that shows the effect of the VLV residues on the formation of oligomers. We, therefore, suggest that the VLV stretches are the 'oligomerization control motifs' of FAP174. As of now, oligomerization and/or dimerization properties of MYCBP-1 and its orthologue FAP174 proteins had not been studied.

To confirm the role of C46 in dimer formation, dithiothreitol (DTT) was used as a reducing agent to cleave the disulfide bridge in the dimer, thus producing a monomer. Upon increasing the molarity of DTT, the concentration of a given protein dimer decreased for FAP174 WT, FAP174VLV21–23AAA and FAP174VLV25–27AAA (Fig. 1A, C and D), requiring ~50 mM for the complete dissociation of the dimer. However, the FAP174C46A variant did not show any tendency to dimerize even at zero DTT (Fig. 1B), confirming the direct involvement of C46 in the dimerization. Similar experiments using the reducing agent DTT were conducted for RiA, wherein 100 mM reduced the dimer to the monomer form.<sup>36</sup>

Raman, CD, and FTIR spectroscopy aided us to understand the structural changes and dimerization in FAP174 WT and its variants (Fig. 2, 4 and 5). The Raman signatures (Fig. 2B) of the dimeric states in the region 500–550 cm<sup>−1</sup> are the peaks at 523 and 546 cm<sup>−1</sup> that correspond to the S–S stretch vibrations of the intermolecular disulfide bond, suggesting a *trans-gauche-trans* geometry<sup>37,38</sup> (Fig. 2B). These two peaks are restricted to FAP174 WT, FAP174VLV21–23AAA and FAP174VLV25–27AAA, in accordance with the formation of dimers.

In all, FAP174 clearly exhibits a tendency to dimerize. Hence, we propose that it belongs to the families of proteins that share certain PPI motifs that mediate dimerization. The dimerization status of FAP174 WT, and the role of the VLV stretches in promoting oligomerization, need to be probed further to understand the implications in cellular function. As of now, no oligomerization motif has been assigned to MYCBP-1 proteins from any organism; the evidence from this study leads us to conclude that FAP174, a ciliary MYCBP-1-like protein, possesses an oligomerization control motif in terms of the VLV stretches.

#### 3.2 FAP174 and the variants are helical proteins

Molecular modeling was carried out primarily to understand the tertiary structure of FAP174 and its three variants. Our predictions show that the replacement of the VLV regions with alanine (two triple variants), or C46 with alanine, have no significant effect on the secondary structure of the three variants *vis-à-vis* the WT protein (Fig. 3). Among the five methods used to predict the secondary structure, we observed a high consensus (Fig. S4–S7†), strengthening our confidence in the predictions. We observed a low/medium agreement in the predictions for regions of random coil, more specifically at the interface of the helix and the random coil. These ambiguities are common, as these uncertainties are also observed in experimentally solved structures; consequently, these uncertainties are also reflected in the computational predictions that are based on those experimental data. The predicted helical content for all structures is in the range of 68–70%.








Fig. 1 Effect of increasing concentration of dithiothreitol (DTT) on the dimerization of (A) FAP174 WT, (B) FAP174C46A, (C) FAP174VLV21-23AAA and (D) FAP174VLV25AAA. The numbers above each lane are concentrations of DTT in mM.




Fig. 2 Raman Spectroscopy of FAP174 and variant proteins. (A) Raman spectra of (a) FAP174 WT, (b) FAP174VLV21-23AAA, (c) FAP174VLV25-27AAA and (d) FAP174C46A recorded in the spectral region of 500–1700  $\text{cm}^{-1}$ . (B) Micro-Raman spectra of (a) FAP174 WT, (b) FAP174VLV21-23AAA, (c) FAP174VLV25-27AAA and (d) FAP174C46A in the spectral region of 880–1000  $\text{cm}^{-1}$ . (C) Micro-Raman spectra of (a) FAP174 WT, (b) FAP174VLV21-23AAA, (c) FAP174VLV25-27AAA and (d) FAP174C46A in the spectral region of 500–1000  $\text{cm}^{-1}$ .

The helical content was validated experimentally using three techniques (CD spectroscopy, FT-IR, and micro-Raman spectroscopy). FT-IR spectroscopy confirmed the predictions (Fig. 4).

The FT-IR spectra of FAP174 WT and the variant proteins in the spectral region 1000–4000  $\text{cm}^{-1}$  indicate the presence of the  $\alpha$ -helix amide I band at  $\sim 1658 \text{ cm}^{-1}$ <sup>39</sup> and the amide II band near



Residue Numbering	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
WT	M	S	E	S	Q	K	E	T	F	R	K	Y	L	E	Q	A	G	A	I	D	V	L	V	K	V	L
Secondary Structure	C	C	c	h	H	H	H	H	H	H	H	H	H	h	h	C	c	H	H	H	H	H	H	H	H	H
VLV21-23AAA mut	M	S	E	S	Q	K	E	T	F	R	K	Y	L	E	Q	A	G	A	I	D	A	A	A	K	V	L
Secondary Structure	C	C	c	h	H	H	H	H	H	H	H	H	H	h	h	C	C	H	H	H	H	H	H	H	H	H
VLV25-27AAA mut	M	S	E	S	Q	K	E	T	F	R	K	Y	L	E	Q	A	G	A	I	D	V	L	V	K	A	A
Secondary Structure	C	C	c	h	H	H	H	H	H	H	H	H	H	h	h	C	C	H	H	H	H	H	H	H	H	H
C46A mut	M	S	E	S	Q	K	E	T	F	R	K	Y	L	E	Q	A	G	A	I	D	V	L	V	K	V	L
Secondary Structure	C	C	c	h	H	H	H	H	H	H	H	H	H	h	h	C	C	H	H	H	H	H	H	H	H	H
Residue Numbering	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52
WT	V	Q	L	Y	E	E	P	S	K	P	K	T	A	L	D	Y	I	K	Q	C	L	G	S	P	T	P
Secondary Structure	H	H	h	h	c	C	C	C	C	c	c	c	h	H	H	H	H	h	h	c	c	c	c	c	h	
VLV21-23AAA mut	V	Q	L	Y	E	E	P	S	K	P	K	T	A	L	D	Y	I	K	Q	C	L	G	S	P	T	P
Secondary Structure	H	H	H	h	C	C	C	C	C	c	c	c	h	H	H	H	H	H	h	c	c	c	c	c	h	
VLV25-27AAA mut	A	Q	L	Y	E	E	P	S	K	P	K	T	A	L	D	Y	I	K	Q	C	L	G	S	P	T	P
Secondary Structure	H	H	H	h	C	C	C	C	C	c	c	c	h	H	H	H	H	H	h	c	c	c	c	C	h	
C46A mut	V	Q	L	Y	E	E	P	S	K	P	K	T	A	L	D	Y	I	K	Q	A	L	G	S	P	T	P
Secondary Structure	H	H	H	h	c	C	C	C	C	c	c	c	h	H	H	H	H	H	h	c	c	c	c	c	c	
Residue Numbering	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78
WT	A	E	Y	E	A	V	V	A	E	R	D	G	L	Q	K	Q	L	E	E	A	N	Q	L	I	A	E
Secondary Structure	h	h	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H
VLV21-23AAA mut	A	E	Y	E	A	V	V	A	E	R	D	G	L	Q	K	Q	L	E	E	A	N	Q	L	I	A	E
Secondary Structure	h	h	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H
VLV25-27AAA mut	A	E	Y	E	A	V	V	A	E	R	D	G	L	Q	K	Q	L	E	E	A	N	Q	L	I	A	E
Secondary Structure	h	h	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H
C46A mut	A	E	Y	E	A	V	V	A	E	R	D	G	L	Q	K	Q	L	E	E	A	N	Q	L	I	A	E
Secondary Structure	h	h	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H
Residue Numbering	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93											
WT	L	Q	S	R	V	Q	S	L	E	A	A	A	E	T	A											
Secondary Structure	H	H	H	H	H	H	h	c	c	c	c	c	c	c	c											
VLV21-23AAA mut	L	Q	S	R	V	Q	S	L	E	A	A	A	E	T	A											
Secondary Structure	H	H	H	H	H	H	C	c	c	c	c	c	c	c	c											
VLV25-27AAA mut	L	Q	S	R	V	Q	S	L	E	A	A	A	E	T	A											
Secondary Structure	H	H	H	H	H	H	h	c	c	c	c	c	c	c	c											
C46A mut	L	Q	S	R	V	Q	S	L	E	A	A	A	E	T	A											
Secondary Structure	H	H	H	H	H	h	C	c	c	c	c	c	c	c	c											
Coil low confidence																										
coil high confidence																										
Helix high confidence																										
Helix low confidence																										

Fig. 3 Consensus secondary structure of WT FAP 174 and its three variants. Prediction of the secondary structure of FAP174 WT and its variant proteins using multiple prediction tools.

1540  $\text{cm}^{-1}$ , which refers to bending of the N-H groups.<sup>40</sup> The band due to Tyr ( $\nu\text{C-C}$  mode) is seen at  $\sim 1520 \text{ cm}^{-1}$  and overlaps with the amide II band.<sup>41</sup> The micro-Raman spectra of all proteins were recorded in the 500–1800  $\text{cm}^{-1}$  range (Fig. 2A); detailed assignments are listed in the ESI Table S1.† In all spectra, a broad band around 1600–1700  $\text{cm}^{-1}$  is very prominent. The peak near 1650–1660  $\text{cm}^{-1}$  is the amide I band, a signature for the  $\alpha$ -helix as previously reported by Spiro and Gaber.<sup>37,42</sup> This observation is in accordance with the computational work that shows all FAP174 proteins (WT and the variants) are largely made of  $\alpha$ -helices with no signs of  $\beta$ -sheets. The band in the region 1200–1300  $\text{cm}^{-1}$  corresponds to amide III.<sup>37,43</sup> A low frequency amide III band ( $\sim 1250 \text{ cm}^{-1}$ ) indicates a lower  $\alpha$ -helical content, whereas the high frequency ( $\sim 1300 \text{ cm}^{-1}$ ) band is an indicator of higher  $\alpha$ -helical content. A band at 1280  $\text{cm}^{-1}$  for the FAP174 WT and the variant proteins

indicate an intermediate  $\alpha$ -helical content, in tune with the computational predictions (*vide supra*). Inspecting the amide I band for all proteins shows that the FAP174VLV21-23AAA and FAP174VLV25-27AAA variants have pronounced peaks at 1655 and 1657  $\text{cm}^{-1}$ , in addition to the peak at 1651  $\text{cm}^{-1}$ . These additional frequencies at 1655 and 1657  $\text{cm}^{-1}$  arise due to the contribution of ordered  $\alpha$ -helix. Thus, compared to FAP174 WT and the FAP174C46A variant, the FAP174VLV21-23AAA and FAP174VLV25-27AAA variants have more ordered  $\alpha$ -helical structure. These observations are comparable with BSA containing high amount of alpha helix as secondary structure.<sup>37</sup> In contrast, the FAP174 WT and the FAP174C46A variant proteins show a single peak at 1651  $\text{cm}^{-1}$ . Besides differences in the preference for oligomerization, this is the second prominent difference between FAP174 WT and the FAP174C46A variant on the one hand and the two VLV variants on the other. Another






Fig. 4 Secondary structure of FAP174 and variants. The secondary structures of (A) FAP174 WT, (B) FAP174VLV21-23AAA, (C) FAP174VLV25-27AAA and (D) FAP174C46A were studied using FTIR spectroscopy – expressed in the units of absorption (Abs) in the spectral range of 1000–4000  $\text{cm}^{-1}$ .

important band which appears around 930–945  $\text{cm}^{-1}$  in the micro-Raman spectra is due to C–C and C–N stretching and is also ascribed to the  $\alpha$ -helical structure of proteins;<sup>42,44</sup> all proteins exhibit a band at 934  $\text{cm}^{-1}$ .

The Raman spectra of proteins usually display prominent modes corresponding to the aromatic amino acids. The ratio of the intensity of the tyrosine bands at 850  $\text{cm}^{-1}$  and 828  $\text{cm}^{-1}$  ( $I_{850}/I_{828}$ ), which usually varies between 0.3 and 2.5, can be used as a marker to investigate the H-bonding state of the tyrosine hydroxyl group. In all four proteins, two bands due to Tyr are observed near 848 and 826  $\text{cm}^{-1}$ , possibly due to the Fermi resonance splitting. The  $I_{850}/I_{828}$  ratio for all proteins is  $\sim 1.1$ , indicating that Tyr is exposed and acts both as a donor and acceptor. Of the 93 a.a. in the FAP174 WT, 12 are alanine, FAP174C46A possesses 13, and FAP174VLV21-23AAA and FAP174VLV25-27AAA contain 15 alanines each. Typically, alanine exhibits a N–C $\alpha$ –C $\beta$  bond stretch at 908  $\text{cm}^{-1}$ , C $\alpha$ –C $\beta$ –H valence angle bending at 1105  $\text{cm}^{-1}$  and CH<sub>3</sub> asymmetric bending at  $\sim 1457$   $\text{cm}^{-1}$  as characteristic frequencies. Peaks at  $\sim 1105$  and  $\sim 1457$   $\text{cm}^{-1}$  are observed in all proteins, indicating C $\alpha$ –C $\beta$ –H valence angle bending and CH<sub>3</sub> asymmetric bending of the methyl group of alanine. Although replacing the VLV with alanine did not lead to major secondary structural changes, a strong peak at 902  $\text{cm}^{-1}$  (Fig. 2C), which as stated previously is the stretching of the N–C $\alpha$ –C $\beta$  bond of alanine, is observed only in the FAP174VLV21-23AAA and FAP174VLV25-27AAA variants;<sup>45</sup> this is the third prominent difference between the VLV variants *vis-à-vis* FAP174 WT and the FAP174C46A variant. It may be emphasized that all proteins of the RII superfamily, including RIIa of PKA and DPY-30, contain two helices in their N-terminus that form the D/D fold.<sup>46,47</sup>

**Qualitative and quantitative analysis of the secondary structure content of FAP174 WT and its variants using circular dichroism.** CD spectroscopy in the near and far UV (180 to 320 nm) region provides qualitative and quantitative information pertinent to the secondary structure of proteins and peptides,<sup>48</sup> for instance, a positive band at 193 nm and negative bands at

208 and 222 nm can be assigned to a  $\alpha$ -helical structure.<sup>49</sup> The qualitative analysis of far UV CD spectra of FAP174 WT and variants (Fig. 5A) was performed, and it demonstrated a positive band at 192 nm and negative bands at 208 and 221 nm. This confirms the  $\alpha$ -helical nature of recombinant FAP174 WT and its variants.

Further quantification of the secondary structure of recombinant FAP174 WT and its variants was carried out by deconvoluting the spectra using the BeStSel webserver. This webserver provides a reference set that contains CD spectra of 73 proteins.<sup>14</sup> The quantification (Fig. 5B–E) revealed, in agreement with the qualitative analysis, a relatively high amount of  $\alpha$ -helix, *i.e.* up to 65%. Of these, the regular helix (H1, Table 2) was about 48%, while the shorter helix (H2, Table 2) was about 18%. In contrast, only  $\sim 4\%$  of anti-parallel  $\beta$ -sheets, no parallel  $\beta$ -sheets,  $\sim 8\%$  of  $\beta$ -turns, and  $\sim 27\%$  of unordered structures were present in the protein (Table 2). The goodness of fit obtained for the given experimental data is shown in Fig. 5B–E and corroborated by a normalized root mean square deviation (NRMSD) as low as 0.010.<sup>50,51</sup>

In all, the qualitative and quantitative results obtained from the CD spectra of FAP WT and variants are in good agreement with MD simulations, Raman and FT-IR spectroscopy studies.




Fig. 5 Secondary structure of FAP174 and variants. The secondary structures of FAP174 WT, FAP174VLV21-23AAA, FAP174VLV25-27AAA and FAP174C46A were studied using CD spectroscopy – expressed in the units of delta epsilon ( $\Delta\epsilon$ ) in the spectral range of 190–250 nm. (A) Far UV CD spectra of FAP174 WT and mutants in 10 mM sodium phosphate buffer, pH 7.0. Experimental and fitted CD spectra of (B) FAP174 WT, (C) FAP174C46A, (D) FAP174VLV21-23AAA, and (E) FAP174VLV25-27AAA. Note the goodness of fit.






**Table 2** Secondary structure calculated from BeStSel webserver. H1 – Helix 1, H2 – Helix 2, APB – Anti-parallel  $\beta$  sheets, PB – Parallel  $\beta$  sheets, Trn – Turns, Unrd – Unordered, RMSD – Root Mean Square Deviation and NRMSD – Normalized Root Mean Square Deviation

Protein	Fraction of each secondary structure in percentages						RMSD	NRMSD
	H1	H2	APB	PB	Trn	Unrd		
FAP WT	47	18	2.0	0.0	6.0	27	0.312	0.010
% total SS	65		2.0					
FAP174C46A	46	16	4.0	0.0	7.0	27	0.295	0.010
% total SS	62		4.0					
FAP174 VLV21-23AAA	48	17	2.0	0.0	6.0	27	0.291	0.009
% total SS	65		2.0					
FAP174 VLV25-27AAA	45	18	2.0	0.0	8.0	27	0.199	0.007
% total SS	63		2.0					

### 3.3 Tertiary structure prediction and refinement by MD simulations

As FAP174 is an orthologue of MYCBP-1, similarities in structure and function between these two proteins are expected. *In vitro* experiments have shown that recombinant FAP174 interacts with the ciliary AKAP240.<sup>12</sup> Of specific interest is the fact that, just like DPY-30 and RII $\alpha$  Dimerization and Docking domains (D/D), MYCBP-1 also binds to AKAPs.<sup>13,52</sup> Thus, it was of interest to unravel the relationship between FAP174 and DPY-30 as well as RII $\alpha$  D/D. The structures of DPY-30 and RII $\alpha$  D/D have been resolved by X-ray crystallography, and a comparison of the 3D structures of FAP174 WT with DPY-30 and RII $\alpha$  D/D facilitated identification of the best model for FAP174 WT. Moreover, the FAP174 protein has a topology like DPY-30 and RII $\alpha$  D/D (Fig. 6A–F), at least in the regions we hypothesize to be the oligomerization control motifs (cyan regions in Fig. 6A–F) and the regions in the vicinity of C46 that are involved in dimerization (magenta regions in Fig. 6A–F). The similarity between FAP174 and DPY-30 and RII $\alpha$  D/D is seen for both the QUARK (model ranked 3) and I-TASSER (model ranked 4) models (all atom RMSD  $\sim 3.9$  Å). Furthermore, the helices B and C superimpose well over the DPY-30 and RII $\alpha$  D/D domains. This suggests that the predicted FAP174 tertiary structures possess the necessary structural arrangement prerequisite for binding to AKAPs and dimerization. The QUARK model, which bears a closer resemblance than the I-TASSER model to DPY-30 (all atom RMSD  $\sim 3.0$  Å) and RII $\alpha$  D/D (all atom RMSD  $\sim 2.7$  Å), was selected for refinement by MD simulations and further analysis. An overall topology of the structure of FAP174 WT is presented in Table 3.

To refine our models and understand their dynamical behavior, three independent MD simulations of 1  $\mu$ s length each in explicit TIP3P water were carried out. The changes and the time evolution of the conformations were studied by the backbone RMSD considering three regions – the complete protein (Fig. 7A), non-terminal amino acids (residues 5–87, Fig. 7B), and residues spanning the core (residues 15–65, Fig. 7C). A large backbone-RMSD (Fig. 7A), computed for all 93 amino acid residues, is observed for the FAP174C46A and FAP174VLV21-23AAA variants. This is attributed to large fluctuations in the terminal



**Fig. 6** Models of FAP174 (red ribbons) superimposed on DPY-30 (green ribbons) and RII $\alpha$  Dimerization and Docking domain (blue ribbons). (A and B) FAP174 WT, (C and D) FAP174VLV21-23AAA, and (E and F) FAP174VLV25-27AAA. The cyan region indicates the oligomerization control motifs (VLV regions), and the magenta region depicts residues C46, Y42, and I43.

**Table 3** Predicted topology of FAP174 WT

Helix	Sequence	Loop/turn	Sequence
A	E <sup>3</sup> – A <sup>16</sup>	N-terminal coil	M <sup>1</sup> – S <sup>2</sup>
B	A <sup>18</sup> – E <sup>31</sup>	Turn ab	G <sup>17</sup>
C	T <sup>38</sup> – C <sup>46</sup>	Loop bc	E <sup>32</sup> – K <sup>37</sup>
D	P <sup>52</sup> – R <sup>62</sup>	Loop cd	L <sup>47</sup> – T <sup>51</sup>
E	Q <sup>66</sup> – A <sup>89</sup>	Loop de	D <sup>63</sup> – I <sup>65</sup>
—	—	C-terminal coil	A <sup>90</sup> – A <sup>93</sup>

regions because ignoring the terminal residues from the RMSD analysis resulted in lower values (Fig. 7B and C). Moreover, it is seen that after  $\sim 200$  ns, the core region of all FAP174 variants are structurally stable. However, the core region in the FAP174WT showed the greatest deviation from the initial conformation exemplified by a large average backbone-RMSD of 5.08 Å ( $\pm 0.78$ ), but reaches a plateau beyond  $\sim 250$  ns.








Fig. 7 Backbone-RMSD plots from 1  $\mu$ s MD simulations for (A) all 93 residues of WT FAP174 and the three variants, (B) non-terminal amino acids (residues 5–87), (C) core amino acids (residues 15–65). Blue trace backbone atoms from the FAP174 WT; orange trace backbone atoms from FAP174C46A; grey trace backbone atoms from FAP174VLV21-23AAA and yellow trace backbone atoms from FAP174VLV25-27AAA. (D) Ribbon representation of the FAP174 WT highlighting the oligomerization control motif (cyan region) and residues C46, Y42 and I43 (magenta region). Values in parenthesis in panels (A–C) indicate the mean RMSD over three independent MD trajectories, respectively.

The radius of gyration (RoG) is a good indicator to understand structural changes at a global level of a protein; a decreasing trend indicates compacting tendencies whereas an increasing trend indicates loosening of the structure. The RoG *versus* normalized distribution plot was used to understand the packing tendency of the FAP174 proteins. All FAP174 variants achieved a similar packing distribution that shows sharp maxima at  $\sim 11$  Å for the core regions (Fig. S8A†) and relatively broad maxima that ranged from 12–13 Å for non-terminal amino acids (Fig. S8B†). However, the FAP174VLV21-23AAA mutant shows a slightly skewed distribution for RoG for non-terminal residues with a relatively sharp maximum at  $\sim 14$  Å (Fig. S6B†). The core region compacts well for the VLV mutants compared to the WT and the C46 variant. The primary reason may be the decrease in the bulky groups by substituting VLV with AAA. This pattern is consistent with both VLV mutants whereas the WT and C46 variant (not involving the VLV regions) show a skewed distribution indicating that the core region is not as compact as the VLV variants.

### 3.4 Validation of models using QMEAN server

The QMEAN6 scores with the accompanying Z-scores were employed to assess the improvement in the quality of the

tertiary models after refinement with MD simulations. QMEAN6 scores range from 0 to 1, where a score close to 1 indicates good quality models. The Z-scores describe the comparison of the QMEAN6 score for the query model with those of high-resolution X-ray structures of similar size; herein a positive value indicates a better quality model. Table 4 lists the QMEAN6 scores for all models before and after refinement using MD simulations. The QMEAN6 scores indicate that the MD has either improved the model quality, or the model quality is as good as the model prior to MD simulations. However, the Z-scores indicate that our models do not achieve the high-resolution quality that X-ray structures of similar size are able to achieve. This is to be expected for small proteins, like in the

Table 4 SwissProt QMEAN validation results

Model	QMEAN6 score (Z-score)	
	Before MD refinement	After MD refinement
FAP174 WT	0.68 (−0.53)	0.79 (−0.03)
FAP174VLV21-23AAA	0.72 (−0.26)	0.72 (−1.10)
FAP174VLV25-27AAA	0.70 (−0.37)	0.69 (−1.5)
FAP174C46A	0.71 (−0.30)	0.71 (−1.4)

Table 5 Comparison between MYCBP-1 and FAP174

Features	Mammalian MYCBP-1	<i>C. reinhardtii</i> FAP174
Molecular weight (kDa)	12	10
Secondary structure	$\alpha$ -helices, only C-terminus	$\alpha$ -helices (current study)
Presence of cysteine	None	One
Dimerization and oligomerization status	Not determined	This study
Transcript expression in tissues/cells	Heart, placenta, pancreas, kidney, skeletal muscle	<i>C. reinhardtii</i> cells
Sub-cellular locations & AKAPs that bind	Nucleus (AKAP95), sperm mitochondria (S AKAP84/149), trans-golgi network (BIG1 and BIG2), motile cilia	Flagellar central Pair (AKAP240), basal body (AKAP unidentified) and nucleus (AKAP unidentified)
References	3–8 and 11	12

current case, that share low sequence homology with any other experimentally solved structure, such that only *ab initio* structure prediction could be applied.

### 3.5 Tertiary structure of FAP174

FAP174 WT comprises five helices (helices A–E) and four connecting loops (bc, cd, de and ef). The oligomerization control motif (Fig. 6D magenta colored region) and the cysteine residue (Fig. 6D cyan colored region), by which dimerization occurs, lie in helix B (A18–E31) and helix C (T38–C46), respectively. Helix B forms the central core of the FAP174 WT structure, being partially surrounded by all other helices.

Like DPY-30 and RII $\alpha$  D/D, our models for FAP174 (including the variants) also harbor two  $\alpha$ -helices (helix B and C) connected by a loop bc. These arrangements in DPY-30 and RII $\alpha$  D/D facilitate dimerization.<sup>22,23</sup> All atom RMSDs of  $\sim 1.4$  Å and  $\sim 1.8$  Å are obtained when helices B, C and loop bc of FAP174 are superimposed with those of DPY-30 and RII $\alpha$  D/D, respectively, indicating very similar folds in this region. Based on these results, we propose that the predicted FAP174 structure possesses the DPY-30 and RII $\alpha$  D/D like motif, which can explain the ability of FAP14 to dimerize and then to bind to AKAPs. It has been reported that the hydrophobic groove in the D/D domain forming the dimer interface is made up of L12, L13, Y16, T17, V20, L21, L28, V29, F31, A32, V33, Y35, F36, T37, and L39.<sup>46</sup> Upon comparison of this groove with FAP174, we found 6 out of 15 amino acid residues being similar; these are V25, L26, A39, L40, Y42, and L47. We thus infer that residues A39, L40, Y42, and L47 in the vicinity of C46 might be involved in dimerization of FAP174.

## 4. Conclusion

The evidences obtained from computer simulations and biophysical experiments indicate that the ciliary MYCBP-1-like protein FAP174 is largely made up of helices and under partly reducing and denaturing conditions exists as an equilibrium mixture of dimer and monomer. Otherwise, it exists as an oligomer that is probably made of dimers. Experiments indicate that C46 is responsible for the dimerization of FAP174 by forming a disulfide bridge linking the two monomers. We have also identified an oligomerization control motif (stretches of VLVs) that plays a crucial role for the oligomerization ability of

FAP174 that has not been determined in the mammalian MYCBP-1 (Table 5). This oligomerization tendency of FAP174 appears to have hampered our previous attempts on determining the solution structure using NMR. The FAP174 structure predicted by the *ab initio* method QUARK is suggested to possess a DPY-30- and RII $\alpha$ -like D/D motif, which can explain the ability of FAP14 to dimerize and then to bind to AKAPs (Table 5).

## Conflicts of interest

The authors have no conflict of interest to declare.

## Abbreviations

FAP174	Flagellar associated protein 174
MYCBP-1	MYC-Binding protein-1
AKAP	A-Kinase anchoring protein
PPI	Protein–protein interactions
MD	Molecular dynamics
RoG	Radius of gyration
C $\alpha$ -RMSD	Root mean squared deviation of alpha carbons
RMSF	Root mean squared fluctuation

## Acknowledgements

This work was supported by a grant (Ref No: BT/R3159/RB/10/960/2011) awarded by the Department of Biotechnology, India to SC and JSD. YM acknowledges the stipend received through this grant. The idea of carrying out a study on micro-Raman spectroscopy of a ciliary protein was conceived by Prof. Deepak Mathur from TIFR, India; SC and JD thank him for providing encouragement. JD wishes to thank Mrs Gitanjali Dhotre of the Department of Chemical Sciences, TIFR, Mumbai for help provided in recording the MALDI-TOF spectra of all proteins used in this study. The authors also thank Dr Sameer Maji, Prof. Swati Patankar, and Mr Pradeep Kumar Singh from Indian IIT-Bombay for help in using the CD instrument. EAFM and ECC are indebted to the Department of Science and Technology (DST), Department of Biotechnology (DBT), and Council of Scientific and Industrial Research (CSIR) for financial



assistance for building the computing facilities at the Department of Pharmaceutical Chemistry, Bombay College of Pharmacy. EAFM thanks wholeheartedly the MCBR4 consortium [Heidelberg 2015, Prof. Dr Peter Comba (Heidelberg), Prof. Dr Hendrik Zipse (Munich) and Prof. Dr G. Narahari Sastry (Hyderabad)] for the financial assistance to carry out research at Heinrich Heine University Düsseldorf, Germany.

## References

- 1 D. Cooper, *Biochem. Soc. Trans.*, 2005, **33**, 1319–1322.
- 2 A. Perino, A. Ghigo, J. D. Scott and E. Hirsch, *Circ. Res.*, 2012, **111**, 482–492.
- 3 T. Taira, J. Maëda, T. Onishi, H. Kitaura, S. Yoshida, H. Kato, M. Ikeda, K. Tamai, M. Iguchi-Arigo and M. Sanae, *Genes Cells*, 1998, **3**, 549–565.
- 4 M. Furusawa, T. Onishi, T. Taira, S. Iguchi-Arigo and H. Ariga, *Int. J. Oncol.*, 2000, **16**, 339–384.
- 5 M. Furusawa, T. Ohnishi, T. Taira, S. M. Iguchi-Arigo and H. Ariga, *J. Biol. Chem.*, 2001, **276**, 36647–36651.
- 6 M. Furusawa, T. Taira, S. M. Iguchi-Arigo and H. Ariga, *J. Biol. Chem.*, 2002, **277**, 50885–50892.
- 7 H. Yukitake, M. Furusawa, T. Taira, S. M. Iguchi-Arigo and H. Ariga, *J. Biol. Chem.*, 2002, **277**, 45480–45492.
- 8 R. Ishizaki, H.-W. Shin, S. M. Iguchi-Arigo, H. Ariga and K. Nakayama, *Genes Cells*, 2006, **11**, 949–959.
- 9 M. S. Kapiloff, M. Rigatti and K. L. Dodge-Kafka, *J. Gen. Physiol.*, 2014, **143**, 9–15.
- 10 Y. Xie, H. Wang, Ihsanawati, S. Kishishita, C. Takemoto, K. Murayama, M. Shirozu and S. Yokoyama, 2011, 10.2210/pdb2yy0/pdb.
- 11 G. J. Pazour, N. Agrin, J. Leszyk and G. B. Witman, *J. Cell Biol.*, 2005, **170**, 103–113.
- 12 V. G. Rao, R. B. Sarafdar, T. S. Chowdhury, P. Sivasdas, P. Yang, P. M. Dongre and J. S. D'Souza, *BMC Cell Biol.*, 2016, **17**, 24.
- 13 Y. Chen, B. Wan, K. C. Wang, F. Cao, Y. Yang, A. Protacio, Y. Dou, H. Y. Chang and M. Lei, *EMBO Rep.*, 2011, **12**, 797–803.
- 14 A. Micsonai, F. Wien, L. Kernya, Y.-H. Lee, Y. Goto, M. Réfrégiers and J. Kardos, *Proc. Natl. Acad. Sci. U. S. A.*, 2015, **112**, E3095–E3103.
- 15 C. Cole, J. D. Barber and G. J. Barton, *Nucleic Acids Res.*, 2008, **36**, W197–W201.
- 16 J. A. Cuff, M. E. Clamp, A. S. Siddiqui, M. Finlay and G. J. Barton, *Bioinformatics*, 1998, **14**, 892–893.
- 17 D. T. Jones, *J. Mol. Biol.*, 1999, **292**, 195–202.
- 18 L. J. McGuffin, K. Bryson and D. T. Jones, *Bioinformatics*, 2000, **16**, 404–405.
- 19 A. Roy, A. Kucukural and Y. Zhang, *Nat. Protoc.*, 2010, **5**, 725–738.
- 20 T. Z. Sen, R. L. Jernigan, J. Garnier and A. Kloczkowski, *Bioinformatics*, 2005, **21**, 2787–2788.
- 21 S. Wu and Y. Zhang, *Nucleic Acids Res.*, 2007, **35**, 3375–3382.
- 22 D. Xu and Y. Zhang, *Proteins*, 2012, **80**, 1715–1735.
- 23 X. Wang, Z. Lou, X. Dong, W. Yang, Y. Peng, B. Yin, Y. Gong, J. Yuan, W. Zhou and M. Bartlam, *J. Mol. Biol.*, 2009, **390**, 530–537.
- 24 M. G. Gold, B. Lygren, P. Dokurno, N. Hoshi, G. McConnachie, K. Taskén, C. R. Carlson, J. D. Scott and D. Barford, *Mol. Cell*, 2006, **24**, 383–395.
- 25 D. A. Case, T. E. Cheatham, T. Darden, H. Gohlke, R. Luo, K. M. Merz, A. Onufriev, C. Simmerling, B. Wang and R. J. Woods, *J. Comput. Chem.*, 2005, **26**, 1668–1688.
- 26 D. Case, Q. Cai, D. Cerutti, T. Cheatham III, T. Darden, R. Duke, H. Gohlke, A. Goetz and S. Gusarov, *Journal*, 2014, 29–31.
- 27 J. A. Maier, C. Martinez, K. Kasavajhala, L. Wickstrom, K. Hauser and C. Simmerling, *J. Chem. Theory Comput.*, 2015.
- 28 W. L. Jorgensen, J. Chandrasekhar, J. D. Madura, R. W. Impey and M. L. Klein, *J. Chem. Phys.*, 1983, **79**, 926–935.
- 29 T. Darden, D. York and L. Pedersen, *J. Chem. Phys.*, 1993, **98**, 10089–10092.
- 30 J.-P. Ryckaert, G. Ciccotti and H. J. Berendsen, *J. Comput. Phys.*, 1977, **23**, 327–341.
- 31 D. R. Roe and T. E. Cheatham III, *J. Chem. Theory Comput.*, 2013, **9**, 3084–3095.
- 32 F. Melo and E. Feytmans, *J. Mol. Biol.*, 1998, **277**, 1141–1152.
- 33 P. Benkert, M. Biasini and T. Schwede, *Bioinformatics*, 2011, **27**, 343–350.
- 34 J. Cheng, A. Z. Randall, M. J. Sweredoski and P. Baldi, *Nucleic Acids Res.*, 2005, **33**, W72–W76.
- 35 W. Kabsch and C. Sander, *Biopolymers*, 1983, **22**, 2577–2637.
- 36 P. Banky, L. J.-S. Huang and S. S. Taylor, *J. Biol. Chem.*, 1998, **273**, 35048–35055.
- 37 A. Rygula, K. Majzner, K. M. Marzec, A. Kaczor, M. Pilarczyk and M. Baranska, *J. Raman Spectrosc.*, 2013, **44**, 1061–1076.
- 38 R. W. Williams, *Methods Enzymol.*, 1986, **130**, 311–331.
- 39 C. L. Wilder, A. D. Friedrich, R. O. Potts, G. O. Daumy and M. L. Francoeur, *Biochemistry*, 1992, **31**, 27–31.
- 40 J. Grdadolnik and Y. Maréchal, *Biopolymers*, 2001, **62**, 40–53.
- 41 A. Barth, *Prog. Biophys. Mol. Biol.*, 2000, **74**, 141–173.
- 42 T. G. Spiro and B. P. Gaber, *Annu. Rev. Biochem.*, 1977, **46**, 553–570.
- 43 K. C. Ravindra, B. R. Selvi, M. Arif, B. A. Reddy, G. R. Thanuja, S. Agrawal, S. K. Pradhan, N. Nagashayana, D. Dasgupta and T. K. Kundu, *J. Biol. Chem.*, 2009, **284**, 24453–24464.
- 44 V. Lin and J. Koenig, *Biopolymers*, 1976, **15**, 203–218.
- 45 W. Qian, J. Bandekar and S. Krimm, *Biopolymers*, 1991, **31**, 193–210.
- 46 F. S. Kinderman, C. Kim, S. von Daake, Y. Ma, B. Q. Pham, G. Spraggon, N. H. Xuong, P. A. Jennings and S. S. Taylor, *Mol. Cell*, 2006, **24**, 397–408.
- 47 M. G. Newlon, M. Roy, D. Morikis, D. W. Carr, R. Westphal, J. D. Scott and P. A. Jennings, *EMBO J.*, 2001, **20**, 1651–1662.
- 48 K. Bakshi, M. R. Liyanage, D. B. Volkin and C. R. Middaugh, *Methods and Protocols, Therapeutic Peptides*, 2014, pp. 247–253.





- 49 G. Holzwarth and P. Doty, *J. Am. Chem. Soc.*, 1965, **87**, 218–228.
- 50 L. Whitmore and B. A. Wallace, *Biopolymers*, 2008, **89**, 392–400.
- 51 D. Mao, E. Wachter and B. Wallace, *Biochemistry*, 1982, **21**, 4960–4968.
- 52 W. E. Theurkauf and R. B. Vallee, *J. Biol. Chem.*, 1982, **257**, 3284–3290.

